

MPC-0767 biochemical

MPC-0767

CATALOG #
AAA227583


PRODUCT SYNONYMS


MPC-0767; MPC-0767 biochemical

PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1310540-32-9
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	MPC-0767 (oral administration; 265 mg/kg; single dose) exhibits a improved PK property, the T max, C max, AUC and F% are 1 (h), 21562 ng/mL, 94194 h/ng/mL and 56%, respectively[1]. MPC-0767 (oral administration; 265 mg/kg) demonstrates comparable efficacy in an N-87 xenograft tumor model, the 46% tumor size reduction with no evidence of weight loss in the study animals[1]. MPC-0767 is well tolerated when administered at 252 mg/kg po (equivalent to 200 mg/kg dose of MPC-3100)[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES


Structure

Thalidomide-O-amido-C3-PEG3-C1-NH₂, CAS 1799711-29-7

Structure

Thalidomide-O-amido-C3-PEG3-C1-NH₂, CAS 1799711-29-7

ADDITIONAL INFORMATION

Related Product Information for MPC-0767 biochemical	MPC-0767 is a potent, selective, and orally active hsp90 inhibitor. MPC-0767 is an L-alanine ester prodrug of MPC-3100 with improved chemical stability.
References	1. Lohbeck J, et al. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. Bioorg Med Chem Lett. 2016;26(21):5260-5262. doi:10.1016/j.bmcl.2016.09.048

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

